Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Clinical and Radiographic Response With Combined BRAF-Targeted Therapy in Stage 4 Ameloblastoma
Frederic J. Kaye, Alison Marguerite Ivey, Walter E. Drane, et al.
JNCI Journal of the National Cancer Institute (2014) Vol. 107, Iss. 1, pp. dju378-dju378
Open Access | Times Cited: 129

Showing 1-25 of 129 citing articles:

Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: Odontogenic and Maxillofacial Bone Tumors
John M. Wright, Marilena Vered
Head and Neck Pathology (2017) Vol. 11, Iss. 1, pp. 68-77
Open Access | Times Cited: 609
The world health organization classification of odontogenic lesions: a summary of the changes of the 2022 (5<sup>th</sup>) edition
Merva Soluk Tekkeşin, John M. Wright
Turkish Journal of Pathology (2022)
Open Access | Times Cited: 106
Ameloblastoma: A Review of Recent Molecular Pathogenetic Discoveries
Noah A. Brown, Bryan L. Betz
Biomarkers in Cancer (2015) Vol. 7s2, pp. BIC.S29329-BIC.S29329
Open Access | Times Cited: 106
Ameloblastoma: An Updated Narrative Review of an Enigmatic Tumor
Suhani Ghai
Cureus (2022)
Open Access | Times Cited: 57
Trends in Research of Odontogenic Keratocyst and Ameloblastoma
X.-H. Liu, Nian‐Nian Zhong, Jing‐Rui Yi, et al.
Journal of Dental Research (2025)
Closed Access | Times Cited: 1
Personalized Medicine in the Oncology Clinic: Implementation and Outcomes of the Johns Hopkins Molecular Tumor Board
W. Brian Dalton, Patrick M. Forde, Hyunseok Kang, et al.
JCO Precision Oncology (2017), Iss. 1, pp. 1-19
Open Access | Times Cited: 84
BRAF inhibitor treatment of primary BRAF -mutant ameloblastoma with pathologic assessment of response
Serena Y. Tan, Jonathan R. Pollack, Michael J. Kaplan, et al.
Oral Surgery Oral Medicine Oral Pathology and Oral Radiology (2016) Vol. 122, Iss. 1, pp. e5-e7
Closed Access | Times Cited: 83
BRAF‐V600E expression correlates with ameloblastoma aggressiveness
Eduardo Rodrigues Fregnani, Danyel Elias da Cruz Pérez, Oslei Paes de Almeida, et al.
Histopathology (2016) Vol. 70, Iss. 3, pp. 473-484
Closed Access | Times Cited: 77
Clinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutation
Gustavo dos Santos Fernandes, Daniel M. Girardi, João Paulo Giacomini Bernardes, et al.
BMC Cancer (2018) Vol. 18, Iss. 1
Open Access | Times Cited: 69
ENDOCRINE TUMORS: BRAF V600E mutations in papillary craniopharyngioma
Priscilla K. Brastianos, Sandro Santagata
European Journal of Endocrinology (2015) Vol. 174, Iss. 4, pp. R139-R144
Open Access | Times Cited: 68
Durable treatment of ameloblastoma with single agent BRAFi Re: Clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma
Daniel L. Faden, Alain P. Algazi
JNCI Journal of the National Cancer Institute (2016) Vol. 109, Iss. 1
Open Access | Times Cited: 65
Ameloblastoma: A succinct review of the classification, genetic understanding and novel molecular targeted therapies
Hongyi Adrian Shi, Chee Wee Ng, Chong Teck Kwa, et al.
The Surgeon (2020) Vol. 19, Iss. 4, pp. 238-243
Closed Access | Times Cited: 57
The Molecular Pathology of Odontogenic Tumors: Expanding the Spectrum of MAPK Pathway Driven Tumors
Letícia Martins Guimarães, Bruna Pizziolo Coura, Ricardo Santiago Gomez, et al.
Frontiers in Oral Health (2021) Vol. 2
Open Access | Times Cited: 45
Precision drugging of the MAPK pathway in head and neck cancer
Hoi-Lam Ngan, Chun-Ho Law, Yannie Chung Yan Choi, et al.
npj Genomic Medicine (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 36
Oncogenic signalling pathways in benign odontogenic cysts and tumours
Marina Gonçalves Diniz, Carolina Cavaliéri Gomes, Sílvia Ferreira de Sousa, et al.
Oral Oncology (2017) Vol. 72, pp. 165-173
Open Access | Times Cited: 60
Treatment of ameloblastoma and ameloblastic carcinoma with radiotherapy
William R. Kennedy, John W. Werning, Frederic J. Kaye, et al.
European Archives of Oto-Rhino-Laryngology (2016) Vol. 273, Iss. 10, pp. 3293-3297
Closed Access | Times Cited: 52
Persistent response to vemurafenib in metastatic ameloblastoma with BRAF mutation: a case report
Morgane Broudic-Guibert, Jean‐Yves Blay, Léa Vazquez, et al.
Journal of Medical Case Reports (2019) Vol. 13, Iss. 1
Open Access | Times Cited: 52
Advancements in MAPK signaling pathways and MAPK‐targeted therapies for ameloblastoma: A review
Zhu You, Shao‐Peng Liu, Jing Du, et al.
Journal of Oral Pathology and Medicine (2018) Vol. 48, Iss. 3, pp. 201-205
Closed Access | Times Cited: 50
Current concepts in ameloblastoma-targeted therapies in B-raf proto-oncogene serine/threonine kinase V600E mutation: Systematic review
Rogelio Gónzalez‐Gónzalez, Sandra López‐Verdín, Jesús Lavalle‐Carrasco, et al.
World Journal of Clinical Oncology (2019) Vol. 11, Iss. 1, pp. 31-42
Open Access | Times Cited: 48
Enabling Precision Medicine for Rare Head and Neck Tumors: The Example of BRAF/MEK Targeting in Patients With Metastatic Ameloblastoma
Maxime Brunet, Emmanuel Khalifa, Antoîne Italiano
Frontiers in Oncology (2019) Vol. 9
Open Access | Times Cited: 45
Molecular biological findings of ameloblastoma
Takao Fuchigami, Yusuke Ono, Shosei Kishida, et al.
Japanese Dental Science Review (2021) Vol. 57, pp. 27-32
Open Access | Times Cited: 33
Diagnostic accuracy of immunohistochemistry compared with molecular tests for detection of BRAF V600E mutation in ameloblastomas: Systematic review and meta‐analysis
Allan Vinícius Martins‐de‐Barros, Raíssa Soares dos Anjos, Caio César Gonçalves Silva, et al.
Journal of Oral Pathology and Medicine (2022) Vol. 51, Iss. 3, pp. 223-230
Closed Access | Times Cited: 23
BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature
Marcel Ebeling, Mario Scheurer, Andreas Sakkas, et al.
Medical Oncology (2023) Vol. 40, Iss. 6
Open Access | Times Cited: 15
Neoadjuvant BRAF-targeted therapy for ameloblastoma of the mandible: an organ preservation approach
Shirly Grynberg, Marilena Vered, Ronnie Shapira‐Frommer, et al.
JNCI Journal of the National Cancer Institute (2023) Vol. 116, Iss. 4, pp. 539-546
Closed Access | Times Cited: 15
Molecular pathogenesis of ameloblastoma
Constanza Celia Nieto Marín, Janine Kirby, Keith D. Hunter
Journal of Oral Pathology and Medicine (2024) Vol. 53, Iss. 5, pp. 277-293
Closed Access | Times Cited: 5
Page 1 - Next Page

Scroll to top